Download PDF
Thromb Haemost 1999; 81(05): 775-781
DOI: 10.1055/s-0037-1614570
Rapid Communication
Schattauer GmbH

The P2Y1 Receptor Is Normal in a Patient Presenting a Severe Deficiency of ADP-induced Platelet Aggregation

Further Evidence for a Distinct P2 Receptor Responsible for Adenylyl Cyclase Inhibition
Catherine Léon
2   From the INSERM, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
,
Catherine Vial
2   From the INSERM, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
,
Christian Gachet
2   From the INSERM, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
,
Philippe Ohlmann
2   From the INSERM, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
,
Béatrice Hechler
,
Jean-Pierre Cazenave
2   From the INSERM, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
,
Anna Lecchi
1   France; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital, University of Milano, Italy
,
Marco Cattaneo
1   France; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital, University of Milano, Italy
› Author Affiliations
Further Information

Publication History

Received 06 October 1998

Accepted after resubmission 01 February 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

ADP is a key stimulus inducing platelet shape change and aggregation, a rise in internal calcium and inhibition of adenylyl cyclase. These signaling pathways are thought to be activated by three independent receptors, but to date only the P2Y1 receptor responsible for calcium mobilization and the ionotropic P21 receptor have been identified. We report here the characteristics of the P2Y1 receptor in a patient presenting a selective deficiency of ADP-induced aggregation. Cloning of the P2Y1 gene revealed that the patient’s DNA and mRNA were normal. Pharmacological studies showed that the P2Y1 receptor was expressed and functional in patient’s platelets. Hence, the P2Y1 receptor is not the cause of the impaired ADP-induced platelet aggregation in this patient. The P21 mRNA was also found to be present and normal. These findings add evidence to previous observations suggesting that a third P2 receptor coupled to adenylyl cyclase may be involved in ADP-induced platelet aggregation.

 

  • References

  • 1 Macfarlane DE. Agonists and receptors: adenosine diphosphate. In Responses and Metabolism.. Holmsen H. ed 1987; 19-36.
    PubMedGoogle Scholar
  • 2 Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, Burn-stock G, Barnard EA. Cloning and functional expression of a brain G-protein-coupled ATP receptor.. FEBS Lett 1993; 324: 219-25.
    CrossrefPubMedGoogle Scholar
  • 3 Schachter JB, Li Q, Boyer JL, Nicholas RA, Harden TK. Second messenger cascade specificity and pharmacological selectivity of the human P2Y1 purinoceptor.. Br J Pharmacol 1996; 118: 167-73.
    CrossrefPubMedGoogle Scholar
  • 4 Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The human P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells.. FEBS Lett 1997; 403: 26-30.
    CrossrefPubMedGoogle Scholar
  • 5 Hechler B, Vigne P, Léon C, Breittmayer P, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor.. Mol Pharmacol 1998; 53: 727-33.
    CrossrefPubMedGoogle Scholar
  • 6 Boyer JL, Romero-Avila T, Schachter JB, Harden TK. Identification of competitive antagonists of the P2Y1 receptor.. Mol Pharmacol 1996; 50: 1323-9.
    PubMedGoogle Scholar
  • 7 Hechler B, Léon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for ADP-induced platelet aggregation.. Blood 1998; 92: 152-9.
    PubMedGoogle Scholar
  • 8 Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.. J Biol Chem 1998; 273: 2030-4.
    CrossrefPubMedGoogle Scholar
  • 9 Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation.. FEBS Lett 1998; 422: 291-5.
    CrossrefPubMedGoogle Scholar
  • 10 Humphries RG, Tomlinson W, Ingall AG, Cage PA, Leff P. FPL 66096LT: a novel, highly potent and selective antagonist at human platelet P2T-receptors.. Br J Pharmacol 1994; 113: 1057-63.
    CrossrefPubMedGoogle Scholar
  • 11 Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.. Br J Haematol 1998; 103: 858-66.
    CrossrefPubMedGoogle Scholar
  • 12 Daniel JL, Dangelmaier C, Lin L, Ashby B, Smith B, Kunapuli S. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets.. J Biol Chem 1998; 273: 2024-9.
    CrossrefPubMedGoogle Scholar
  • 13 Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P. P2Y1-receptors in human platelets which are pharmacologically distinct from P2YADP-receptors.. Br J Pharmacol 1998; 124: 157-64.
    CrossrefPubMedGoogle Scholar
  • 14 Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.. Proc Natl Acad Sci USA 1998; 95: 8070-4.
    CrossrefPubMedGoogle Scholar
  • 15 Ohlmann P, Laugwitz K, Nürnberg B, Spicher K, Schultz G, Cazenave JP, Gachet C. The human platelet ADP receptor activates Gi2 proteins.. Biochem J 1995; 312: 775-9.
    CrossrefPubMedGoogle Scholar
  • 16 Vial C, Hechler B, Léon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines.. Thromb Haemost 1997; 78: 1500-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Scase TJ, Heath MF, Allen JM, Sage SO, Evans RJ. Identification of a P2X1 purinoceptor expressed on human platelets.. Biochem Biophys Res Comm 1998; 242: 525-8.
    CrossrefPubMedGoogle Scholar
  • 18 Sun B, Li K, Okahara K, Kambayashi I J. P2X1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression.. J Biol Chem 1998; 273: 11544-7.
    CrossrefPubMedGoogle Scholar
  • 19 Clifford EE, Parker K, Humphreys BD, Kertezy SB, Dubyak GR. The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes.. Blood 1998; 91: 3172-81.
    PubMedGoogle Scholar
  • 20 Mahaut-Smith MP, Sage SO, Rink TJ. Rapid ADP-evoked currents in human platelets recorded with the nystatin permeabilized patch technique.. J Biol Chem 1992; 267: 3060-5.
    PubMedGoogle Scholar
  • 21 MacKenzie A, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets.. J Biol Chem 1996; 271: 2879-81.
    CrossrefPubMedGoogle Scholar
  • 22 Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannuci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.. Blood 1992; 80: 2787-96.
    PubMedGoogle Scholar
  • 23 Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets.. J Clin Invest 1995; 95: 1612-22.
    CrossrefPubMedGoogle Scholar
  • 24 Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Manucci PM, Cazenave JP. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.. Br J Haematol 1995; 91: 434-44.
    CrossrefPubMedGoogle Scholar
  • 25 Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave JP Mannucci PM. Deficiency of [ 33 P]2MeSADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production.. Thromb Haemost 1997; 77: 986-90.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Cazenave JP, Hemmendinger S, Beretz A, Sutter-Bay A, Launay J. L’agrégation plaquettaire: outil d’investigation clinique et d’étude pharmacologique. Méthodologie.. Ann Biol Clin 1983; 41: 167-79.
    PubMedGoogle Scholar
  • 27 Léon C, Vial C, Cazenave JP, Gachet C. Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor.. Gene 1996; 171: 295-7.
    CrossrefPubMedGoogle Scholar
  • 28 Sambrook J, Fritsh EF, Maniatis T. Molecular cloning. A laboratory manual.. Cold Spring Harbor Laboratory Press 1989
    PubMedGoogle Scholar
  • 29 Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems.. Anal Biochem 1980; 107: 220-39.
    CrossrefPubMedGoogle Scholar
  • 30 Breathnach R, Chambon P. Organization and expression of eukaryotic split genes coding for proteins.. Annu Rev Biochem 1981; 50: 349-83.
    CrossrefPubMedGoogle Scholar
  • 31 Ayyanathan K, Webbs TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. Cloning and chromosomal localization of the human P2Y1 purinoceptor.. Biochem Biophys Res Commun 1996; 218: 783-8.
    CrossrefPubMedGoogle Scholar
  • 32 Lanza F, Beretz A, Stierlé A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregating agent.. Am J Physiol 1988; 255: 1276-88.
    PubMedGoogle Scholar
  • 33 Savi P, Pflieger AM, Herber JM. cAMP is not an important messenger for ADP-induced platelet aggregation.. Blood Coag Fibrin 1996; 7: 249-52.
    CrossrefPubMedGoogle Scholar
  • 34 Lévy-Toledano S, Maclouf J, Rosa J-P, Gallet C, Vallès G, Nurden P, Nur-den AT. Abnormal tyrosine phosphorylation linked to a defective interaction between ADP and its receptor on platelets.. Thromb Haemost 1998; 80: 463-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Savi P, Artçanuthurry V, Bornia J, Grelac F, Maclouf J, Levy-Toledano S, Herbert J-M.. Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets.. Brit J Haematol 1997; 97:: 185-91.
    CrossrefPubMedGoogle Scholar